[go: up one dir, main page]

Kim et al., 2021 - Google Patents

Comparative analysis of the expression of chondroitin sulfate subtypes and their inhibitory effect on axonal growth in the embryonic, adult, and injured rat brains

Kim et al., 2021

View PDF
Document ID
260081966682930140
Author
Kim M
Park S
Choi B
Publication year
Publication venue
Tissue Engineering and Regenerative Medicine

External Links

Snippet

Background: Chondroitin sulfate glycosaminoglycans (CS-GAGs) are the primary inhibitory GAGs for neuronal growth after central nervous system (CNS) injury. However, the inhibitory or permissive activity of CS-GAG subtypes is controversial and depends on the physiological …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Preston et al. Neural stem cell niches: critical roles for the hyaluronan-based extracellular matrix in neural stem cell proliferation and differentiation
Alonge et al. Hypothalamic perineuronal net assembly is required for sustained diabetes remission induced by fibroblast growth factor 1 in rats
Djerbal et al. Chondroitin sulfates and their binding molecules in the central nervous system
Anderson et al. Astrocyte scar formation aids central nervous system axon regeneration
Zhao et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice
Struve et al. Disruption of the hyaluronan‐based extracellular matrix in spinal cord promotes astrocyte proliferation
Yi et al. Alterations in sulfated chondroitin glycosaminoglycans following controlled cortical impact injury in mice
Hayes et al. Glycans and glycosaminoglycans in neurobiology: key regulators of neuronal cell function and fate
Zhang et al. N-Acetylglucosamine 6-O-sulfotransferase-1 is required for brain keratan sulfate biosynthesis and glial scar formation after brain injury
Zhang et al. Brain keratan sulfate and glial scar formation
Jang et al. Extracellular matrixes and neuroinflammation
Srivastava et al. Dysregulation of hyaluronan homeostasis during white matter injury
Jokela et al. Mannose reduces hyaluronan and leukocytes in wound granulation tissue and inhibits migration and hyaluronan‐dependent monocyte binding
Takechi et al. A pericellular hyaluronan matrix is required for the morphological maturation of cortical neurons.
Kim et al. Comparative analysis of the expression of chondroitin sulfate subtypes and their inhibitory effect on axonal growth in the embryonic, adult, and injured rat brains
CA2851761A1 (en) Method of diagnosis, prognostic or treatment of neurodegenerative diseases
Blake et al. Chondroitin sulfate proteoglycan 4, 6 sulfation regulates sympathetic nerve regeneration after myocardial infarction
Bedini et al. Chondroitin, dermatan, heparan, and keratan sulfate: Structure and functions
Venkatesan et al. Increased deposition of chondroitin/dermatan sulfate glycosaminoglycan and upregulation of β1, 3-glucuronosyltransferase I in pulmonary fibrosis
Li et al. Targeting ANXA7/LAMP5-mTOR axis attenuates spinal cord injury by inhibiting neuronal apoptosis via enhancing autophagy in mice
Huang et al. Local injection of high-molecular hyaluronan promotes wound healing in old rats by increasing angiogenesis
Wang et al. Schisandrin B attenuates bleomycin-induced pulmonary fibrosis in mice through the wingless/integrase-1 signaling pathway
Zhang et al. The Role of SREC-Ⅰ in innate immunity to aspergillus fumigatus Keratitis
US8092825B2 (en) Glycan binding proteins as therapeutic targets for retinal disorders and treatment methods based thereon
Yin et al. Transforming growth factor-β1 upregulates keratan sulfate and chondroitin sulfate biosynthesis in microglias after brain injury